Results 151 to 160 of about 231,717 (193)

Transthyretin amyloid cardiomyopathy: from cause to novel treatments. [PDF]

Eur Heart J
Fontana M, Aimo A, Emdin M, Porcari A, Solomon SD, Hawkins PN, Gillmore JD.   +6 more
europepmc   +1 more source

Right Atrial Function as a Novel Predictor for New-Onset Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy. [PDF]

J Am Heart Assoc
Kuyama N, Izumiya Y, Takashio S, Usuku H, Tabira A, Kondo H, Saito S, Yonezu K, Kodama N, Zaizen T, Yamasaki H, Suiko Y, Ogata M, Matsuura Y, Tsuruda T, Ishii M, Yamamoto M, Hirakawa K, Kanazawa H, Hoshiyama T, Kidoh M, Oda S, Hanatani S, Matsuzawa Y, Yamamoto E, Ueda M, Takahashi N, Kaikita K, Tsujita K.   +28 more
europepmc   +1 more source

Serum Transthyretin as a Prognostic and Therapeutic Biomarker in Transthyretin Amyloid Cardiomyopathy Patients Treated with Tafamidis. [PDF]

J Clin Med
Costantino J, Ballatore F, Marchionni G, Alfarano M, Stavagna S, Costantino S, Vizza CD, Chimenti C.   +7 more
europepmc   +1 more source

Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report. [PDF]

Front Cardiovasc Med
Song B, He Y, Liu X, Liu H, Du F, Wang J, Tan H, Zhang C, Zhang P.   +8 more
europepmc   +1 more source

Prediagnostic Electrocardiographic Abnormalities in Transthyretin Amyloid Cardiomyopathy: A Longitudinal Observational Study. [PDF]

J Clin Med
Venkateshvaran A, Karaoglu HM, Pilebro B.   +2 more
europepmc   +1 more source

Development of a Predictive Tool in Patients With High Pretest Probability for Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Chai J, Starovoytov A, Worsley D, Fine NM, Peng D, Virani S, Davis MK.   +6 more
europepmc   +1 more source

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy [PDF]

New England Journal of Medicine, 2018
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and amyloidogenesis.In a multicenter, international, double-blind, placebo ...
Mathew S Maurer, Arnt V Kristen, Giampaolo Merlini   +2 more
exaly   +8 more sources

Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice [PDF]

JACC: Heart Failure, 2019
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive, infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and can often be overlooked as a common cause of heart failure. Delayed diagnosis due to lack of disease awareness and misdiagnosis results in a poorer prognosis.
Laura Obici, Ronald Witteles, Rodney H Falk   +2 more
exaly   +10 more sources

Some of the next articles are maybe not open access.

Related searches:

Transthyretin amyloid cardiomyopathy

Medicina Clínica (English Edition), 2021
Transthyretin (TTR) cardiac amyloidosis is a severe, progressive, infiltrative disease caused by the deposition of TTR at cardiac level. It may be due to a genetic alteration in its hereditary form (ATTRv) or as a consequence of an age-related degenerative process (ATTRwt). Thanks to advances in imaging techniques and the possibility of achieving a non-
Pablo, Garcia-Pavia, Fernando, Domínguez, Esther, Gonzalez-Lopez   +2 more
openaire   +4 more sources